Application of Molecular and Genomic Biomarker Testing in Solid Tumors-Recorded Webinar

Video Transcription

Video Summary

Dr. Marilyn Bui moderates a session on precision medicine within the Florida Society of Pathologists, focusing on molecular and genomic biomarker testing in solid tumors. The educational event offers CME credits and is supported by grants from AstraZeneca. The program emphasizes enriching multidisciplinary communication, particularly between pathologists and medical oncologists.<br /><br />Distinguished faculty, Dr. Newsome and Dr. Terry Boyle, deliver lectures on the methodologies, clinical utility, and interpretation of molecular and genomic testing in solid tumors. Dr. Newsome introduces molecular and genomic biomarker testing and highlights clinically actionable biomarkers like HER2 and CLAUDIN 18.2, discussing the methodologies such as PCR and next-generation sequencing.<br /><br />Dr. Boyle discusses the clinical utility of molecular testing and the importance of comprehensive genomic profiling to guide treatment plans. Recent FDA approvals for site-agnostic cancer treatments underscore the necessity for broad molecular testing, empowering personalized treatment beyond traditional cancer-specific strategies. She emphasizes accurate interpretation of test results using standardized guidelines and resources like ClinVar and OncoKB.<br /><br />The session concludes with a Q&amp;A addressing practical concerns like prioritizing tests when tissue samples are limited and evaluating test quality in community settings. The FSP Learning Center is introduced as a hub for ongoing education, supporting pathologists with resources and CME credits. The next session scheduled will cover molecular biomarker testing in hematopathology, continuing the emphasis on precision medicine.

Keywords

precision medicine

molecular testing

genomic biomarkers

solid tumors

CME credits

HER2

next-generation sequencing

FDA approvals

ClinVar

OncoKB